Descriptive study on the presence, treatment and evolution of comorbidities in a series of 200 migraine patients treated with fremanezumab.

Abstract text (incl. figure legends and references)

Introduction: Clinical trials do not yield information on whether mo-noclonal antibodies against CGRP (MABS) interact with other drugs or influence the evolution of patients' comorbidities.

Methods: Prospective observational study aimed to describe the relationship of frema-nezumab with comorbidities and their respective treatments.

Results: We included 200 patients on fremanezumab treatment for at least 3 months, 165 with chronic migraine (CM), 35 with high-frequency episodic migraine (HFM). Comorbidities were present in 73.3% of patients with CM and 45.7% with HFM, the most frequent being depression (21.2%), insomnia (11.6%) and anxiety (9.7%). HT was present in 7.3% of the sample. After 6 months of treatment 28.7% improved and 15% worsened anxiety and depression, the rest were stable. Only 1 case reported the appearance of HT as an adverse effect. 16 patients with oral contraceptives: no interaction with fremanezumab; 8 patients with immunosuppressants: 87.5% no influence on evolution of comorbidity (myasthenia gravis, asthma), 12.5% worsens polyarthritis; 2 patients with other antibodies: no influence on evolution of comorbidity (rheumatoid arthritis).

Conclusion:

The use of MABS can help to improve comorbidities such as depression or anxiety in patients with migraine.

In our sample there were no complications derived from the combination of frema-nezumab with other monoclonal antibodies, immunosuppressants or oral contraceptives.